Drugs.com Clinical Trial ResultsOriginal article
Jemperli (dostarlimab-gxly) Accepted for Priority Review by the US FDA for dMMR/MSI-H Locally Advanced Rectal Cancer
BLA FilingJemperliPositive
AI Analysis
Summary
GSK announced the FDA accepted for priority review a supplemental BLA for Jemperli (dostarlimab-gxly) in patients with dMMR/MSI-H locally advanced rectal cancer. Priority review status accelerates the regulatory timeline for this indication.
Outcome Details
Supplemental BLA accepted for priority review
Importance:7/10
Sentiment:
0.70
FDA priority reviewoncologyimmunotherapyrectal cancerdMMR/MSI-H
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on August 24, 2026 4:08 AM